This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Zanolimumab

Emergent BioSolutions, Inc.

Drug Names(s): HuMax-CD4

Description: HuMax-CD4 is a high affinity, fully human antibody that targets the CD4 receptor on cells known as T-cells, which are believed to be involved in promoting autoimmune disease.

Deal Structure: Serono and Genmab
Serono and Genmab A/S announced an agreement in August 2005 under which Genmab has granted Serono exclusive worldwide rights to develop and commercialize Genmab's HuMax-CD4.

Under the terms of the agreement, Genmab will receive a license fee of $20 million, and Serono will make a $50 million investment in Genmab common stock, at a premium to the market price. Genmab may receive up to $215 million in total payments. Genmab will be entitled to receive royalties on global sales of HuMax-CD4. Serono will be responsible for all future development costs for HuMax-CD4 and for future manufacturing of the product.

In June 2007, Genmab A/S announced it had regained all rights to the HuMax-CD4 antibody from Merck Serono S.A.

Medarex, Genmab and Bristol-Myers
Medarex received an equity interest in Genmab in exchange for a license of its proprietary antibody technology. In addition, it expects to receive milestone payments for activities in Europe...See full deal structure in Biomedtracker

Partners: Bristol-Myers Squibb Company TenX Biopharma, Inc. Genmab A/S


Zanolimumab News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug